{"product_id":"rxrx-bcg-matrix","title":"(RXRX) Recursion Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Recursion Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to access the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-994, Phase IIa\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-994 is Recursion Pharmaceuticals, Inc.'s most advanced named asset, now in Phase IIa for cerebral cavernous malformation, a rare disease with no approved disease-modifying therapy. That makes it a high-value shot on goal in an area where even small positive data can matter a lot. If the next readout stays positive, REC-994 is one of the clearest near-term upside drivers for Recursion Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-3599, Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-3599 is a Phase I, clinical-stage GM2 gangliosidosis program for Recursion Pharmaceuticals, Inc., with zero current market share and no approved disease-modifying therapy. Early human data can re-rate the asset fast because even a small responder base in this ultra-rare space can shift value. That makes it a high-growth, high-support BCG \"Star\" profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-4881, clinical-stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-4881 is a clinical-stage asset aimed at familial adenomatous polyposis, a rare disease seen in about 1 in 8,000 to 1 in 10,000 births. That puts it in a high-unmet-need niche where a clear clinical win could give Recursion Pharmaceuticals, Inc. a strong specialty position. It is still capital hungry, though, so the program needs ongoing R\u0026amp;D spend and trial support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-2282, clinical-stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-2282 is a clinical-stage NF2 pipeline asset for Recursion Pharmaceuticals, targeting a rare disease that affects about 1 in 25,000 to 33,000 people. With limited current treatment options, a clear efficacy and safety signal could support fast uptake and make it a strong BCG Stars candidate. If approved, it has the profile of a future commercial leader in a small but high-value market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease, high unmet need\u003c\/li\u003e\n\u003cli\u003eLimited competition today\u003c\/li\u003e\n\u003cli\u003eApproval could drive rapid scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAI-enabled drug discovery platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.’s AI-enabled drug discovery platform is the company’s main Star: it blends biology, chemistry, automation, data science, and engineering into one engine for pipeline creation. In 2025, this platform stayed central to R\u0026amp;D, with Recursion reporting cash, cash equivalents, and marketable securities of $610.4 million at year-end, supporting continued investment.\u003c\/p\u003e\n\u003cp\u003eIt is a growth asset because output depends on steady spend on data, compute, and lab scale-up, not just one-off wins. That makes it the base for future programs and partnerships, but it also means margins stay pressured until more candidates move through the pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore differentiated drug discovery engine\u003c\/li\u003e\n\u003cli\u003eNeeds ongoing capital to scale\u003c\/li\u003e\n\u003cli\u003eSupports future pipeline creation\u003c\/li\u003e\n\u003cli\u003eStill in growth investment mode\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s AI-Driven Rare-Disease Stars Have a Well-Funded Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.’s Stars are its late-stage rare-disease assets and AI platform: REC-994 (Phase IIa), REC-3599 (Phase I), REC-4881 (clinical), REC-2282 (clinical), and the Recursion Pharmaceuticals, Inc. platform. At 2025 year-end, Recursion Pharmaceuticals, Inc. held $610.4 million in cash, cash equivalents, and marketable securities, keeping these growth bets funded.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-994\u003c\/td\u003e\n\u003ctd\u003ePhase IIa\u003c\/td\u003e\n\u003ctd\u003eLead near-term upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eCore engine\u003c\/td\u003e\n\u003ctd\u003eFunds pipeline growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eRecursion Pharmaceuticals’ BCG Matrix maps its AI drug pipeline for where to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix snapshot for Recursion Pharmaceuticals, Inc. that highlights pain points and portfolio priorities at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Recursion Pharmaceuticals, Inc., helping investors verify key claims and make faster, better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed drug revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is still clinical-stage, so it has no approved drug and no marketed product revenue to act as a true cash cow. In its latest reported year, the company still relied on collaboration and funding income rather than sales, with revenue mainly from partnerships. That means cash generation is strategic, not product-led, and the BCG cash-cow bucket is effectively empty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer AG collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s Bayer AG collaboration is a cash cow-like asset because it monetizes the platform without a launched drug. The 2019 pact targeted up to $1.2 billion in milestones plus research funding and royalties, with Bayer paying upfront and ongoing discovery support. That kind of external income helps offset Recursion Pharmaceuticals, Inc.'s 2025 net loss of $560.4 million and reduces dependence on product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda Pharmaceutical collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s Takeda Pharmaceutical collaboration is a non-dilutive funding source that helps pay for R and D without adding share dilution. It brings in collaboration revenue tied to partnered programs, so Recursion is less dependent on any single internal asset to fund operations. In BCG terms, this is the closest thing to a cash cow: low-growth, but cash-positive and strategic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUniversity of Utah Research Foundation agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe University of Utah Research Foundation agreement is a low-cost cash-supporting asset for Recursion Pharmaceuticals, Inc. Academic licensing can bring recurring fees and external validation without the spend of a full internal program. For a pre-commercial biotech, that kind of non-dilutive support helps offset R\u0026amp;D burn.\u003c\/p\u003e\n\u003cp\u003eIt is unlikely to move revenue much on its own, but it can steady the base while Recursion scales its pipeline. The real value is cheap maintenance, data access, and credibility with partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring fees\u003c\/li\u003e\n\u003cli\u003eLow upkeep cost\u003c\/li\u003e\n\u003cli\u003eExternal validation\u003c\/li\u003e\n\u003cli\u003eSupports pre-commercial cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOhio State Innovation Foundation agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Ohio State Innovation Foundation agreement gives Recursion Pharmaceuticals, Inc. another non-dilutive support channel, so it can widen its research network without matching that growth with direct commercialization spend. In BCG terms, this looks more like a steady funding stream than a cash-heavy development asset, especially since Recursion reported $1.0 billion in cash, cash equivalents, and marketable securities as of Q1 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal scientific support\u003c\/li\u003e\n\u003cli\u003eLower direct burn\u003c\/li\u003e\n\u003cli\u003eSteadier funding profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s “Cash Cows” Are Really Partnerships, Not Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has no true cash cows because it remains pre-commercial and depends on collaboration revenue, not product sales. Its closest cash-cow-like assets are Bayer AG and Takeda Pharmaceutical partnerships, which bring non-dilutive funding that helps offset the 2025 net loss of $560.4 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 cash\u003c\/td\u003e\n\u003ctd\u003e$1.0 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 net loss\u003c\/td\u003e\n\u003ctd\u003e$560.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash cow status\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRecursion Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Recursion Pharmaceuticals, Inc. BCG Matrix report you'll receive after purchase. The file is the same final document—fully formatted, ready to use, and free of demo content or watermarks. Once purchased, it’s instantly available for download and immediate application in your analysis, presentation, or strategy planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. had no approved products in the set, so there was no marketed therapeutic franchise to classify as a commercial Dog. Without an approved asset, there is no mature market share or durable product cash flow to harvest or exit; 2025 revenue was still driven by collaboration income, not product sales. That keeps Recursion Pharmaceuticals, Inc. in a pipeline-only state, with no true Dog to manage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo recurring product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. still has no recurring product sales, so it cannot use a mature cash cow to fund growth. The latest filings show revenue comes from collaborations, not a commercial product base, which is a structural drag in BCG terms. With no legacy brand to harvest, each program still depends on R\u0026amp;D spend and future approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R and D cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. spent about $395 million on R\u0026amp;D in 2024, while revenue was only about $58 million, so cash burn far outpaced cash generation. The company also reported a net loss of about $718 million, which shows how clinical and preclinical work can drain capital long before products reach market. In BCG terms, this fits a dog profile when assets do not move forward fast enough to offset the burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly-stage competitive programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has several early-stage competitive programs that are still preclinical, so they have not yet shown human efficacy. In crowded fields, low share can stick for years, and the math is harsh: one weak readout can erase years of optionality. If new data do not improve, these assets can become value traps rather than BCG-style \"Dogs\".\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical only; no human efficacy yet\u003c\/li\u003e\n\u003cli\u003eCrowded markets can delay share gains\u003c\/li\u003e\n\u003cli\u003eWeak data can trap capital for years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePre-commercial biotech model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is still pre-commercial, so most value is tied to pipeline progress, not product sales. That keeps the model dependent on outside capital and partner funding, and unvalidated programs still carry a dog-like downside until approvals land. Latest filings still show heavy R\u0026amp;D spend and no mature launch revenue base, so execution risk remains high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-commercial, not scale commercial\u003c\/li\u003e\n\u003cli\u003ePartner cash matters most\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D burn drives dilution risk\u003c\/li\u003e\n\u003cli\u003eApproval is the key value trigger\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Has No Dog—Just Heavy Burn and No Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has no marketed drug, so it has no true Dog to harvest in BCG terms. FY2025 revenue was about $58 million, while FY2024 R\u0026amp;D spend was about $395 million and net loss about $718 million, showing heavy burn and no cash-generating legacy asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue: $58M\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D: $395M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo product sales\u003c\/td\u003e\n\u003ctd\u003eNet loss: $718M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-3964, preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-3964 is a preclinical bet on Clostridium difficile colitis, a high-need space with about 500,000 U.S. infections and roughly 29,000 deaths a year. It has no human market share yet, so the asset is still a pure Question Mark in the BCG Matrix. Recursion must keep funding heavy R\u0026amp;D before any commercial case is clear.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-64917, preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-64917 is a preclinical bet on neural or systemic inflammation, a scientifically attractive area but still far from proof. At this stage, the odds are tough: industry data show preclinical programs have less than a 10% chance of reaching approval. It can only move from question mark to star if Recursion Pharmaceuticals, Inc. gets strong human safety and efficacy data in the clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-65029, preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-65029 is a classic question mark: it is preclinical, targets HRD-negative ovarian cancer, and has zero share or revenue today. Ovarian cancer remains a large unmet market, with about 324,000 new cases worldwide each year, but competition is crowded and the clinical bar is high, so Recursion Pharmaceuticals, Inc. must prove strong efficacy fast or prune it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-648918, preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-648918 is a Question Mark: it is built to boost anti-tumor immunity, but it is still preclinical, so there is no human proof yet. The oncology market is huge—global cancer drug sales were about $223 billion in 2024—and that makes the prize real, but it also means the bar is high.\u003c\/p\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. must fund expensive preclinical work, IND-enabling studies, and early trials before the asset can move from concept to share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical; no clinical data yet\u003c\/li\u003e\n\u003cli\u003eImmune-oncology angle, high upside\u003c\/li\u003e\n\u003cli\u003eNeeds heavy capital to advance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-2029, preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-2029 is a preclinical bet on wnt-mutant hepatocellular carcinoma, a niche with real upside because liver cancer still causes about 865,000 new cases and 760,000 deaths a year worldwide. But it is still unproven, so the asset sits squarely in the Question Mark bucket: high growth potential, no clinical proof yet, and a real risk of failure.\u003c\/p\u003e\n\u003cp\u003eFor Recursion Pharmaceuticals, Inc., REC-2029 can scale fast only if early biology turns into clear human data; until then, it adds optionality, not earnings. In BCG terms, it is a high-risk, high-reward program with no sales today and no visible path to near-term cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical, no human proof yet\u003c\/li\u003e\n\u003cli\u003eTargets wnt-mutant hepatocellular carcinoma\u003c\/li\u003e\n\u003cli\u003eHigh unmet need, but high failure risk\u003c\/li\u003e\n\u003cli\u003ePotentially large upside if validated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s Preclinical Pipeline: High Upside, High Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s Question Marks are all preclinical, so they have no revenue, no market share, and need heavy cash burn before proof. That makes them high-upside but high-failure assets. In 2025\/2026, they are still value drivers only if early data turn into human efficacy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-3964\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eCDI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-64917\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eInflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-65029\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eOvarian cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-648918\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eImmuno-oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234974933257,"sku":"rxrx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rxrx-bcg-matrix.webp?v=1785730666","url":"https:\/\/dcfanalyst.com\/products\/rxrx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}